Medical/Pharmaceuticals
R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved
BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...
2021-11-15 22:47
3415
Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373
GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company inSouth Korea, today...
2021-11-15 22:39
4561
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted Priority M...
2021-11-15 22:10
7638
Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO Gastrointestinal Cancers Symposium
TAIPEI and SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting clinical design for their lead drug candidate...
2021-11-15 20:00
2323
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention
JIUQUAN, China, Nov. 15, 2021 /PRNewswire/ -- Qilian International Holding
Group Limited (Nasdaq: QLI
2021-11-15 20:00
1833
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...
2021-11-15 20:00
4442
Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing
SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....
2021-11-15 19:00
2332
Vazyme goes public on Shanghai Stock Exchange today
NANJING, China, Nov. 15, 2021 /PRNewswire/ -- On November 15, 2021, Nanjing
Vazyme Biotech Co., Ltd. (Vazyme) went public on the STAR MARKET of the
Shanghai Stock Exchange under the stock code 688105.
2021-11-15 16:28
5093
Labcorp Opens New Integrated Laboratory, Strengthens Bioanalytical Services In Asia-Pacific
SINGAPORE, Nov. 15, 2021 /PRNewswire/ -- Labcorp
2021-11-15 16:00
4223
Qiming's Portfolio Company Aohua Endoscopy Lands on STAR Market
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Aohua Endoscopy (SHSE: 688212), a leading medical endoscope manufacturer, today landed on the STAR Market. The issue price isCNY 22.5 per share. The stock opened atCNY 33 per share, representing a market cap of CNY...
2021-11-15 15:06
3837
CBC Group Partners with APG to Launch Healthcare Real Estate Platform and Announce US$500 Million First Close of China Life Science Venture
SHANGHAI, Nov. 14, 2021 /PRNewswire/ --CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm, announced today a partnership with APG Asset Management ("APG"), the largest pension provider inthe Netherlands, in a newAsia-Pacific healthcare platform, CBC Healthcare Infrastructure P...
2021-11-15 10:08
3524
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA
BEIJING, Nov. 14, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 by the US Food and Drug A...
2021-11-15 08:30
2778
Wision A.I. Achieves CE-MDR Mark Approval for AI-assisted Diagnostic Software Medical Device Supporting Colonoscopy
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Wision A.I. Ltd, a startup in the field of artificial intelligence assisted diagnostics for gastrointestinal endoscopy, today announced it received the European CE Mark approval for EndoScreener, its AI-assisted polyp detection software during colonoscopy. ...
2021-11-15 08:30
2516
Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC) has been approved by China National ...
2021-11-15 08:30
3508
Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021
-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in checkpoint inhibitor resistant/relapsed models while mitigating liver toxicity risk, computational analysis adds support to dosing strategy -ATG-017, an ERK1/2 inhibitor, in vivo combination supports c...
2021-11-15 08:25
3804
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-11-15 08:00
3719
$5M Boost to Innovation in Australia with New Illumina Genomics Lab
New laboratory opens in Melbourne Biomedical Precinct to accelerate the adoption of genomics in healthcare and agriculture inAustralia. MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), the global leader in genomics, today announced the opening of a new, fully eq...
2021-11-15 06:14
7112
Ascensia Diabetes Care Announce Winner of This is Diabetes Art and Photo Competition
BASEL, Switzerland, Nov. 14, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, makers of CONTOUR® blood glucose monitoring (BGM) system portfolio and distributors of the Eversense® continuous glucose monitoring (CGM) system, has announced the winner of its This is Diabe...
2021-11-14 15:00
3188
China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results
HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...
2021-11-13 05:30
5485
Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...
2021-11-13 02:56
5370
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 325 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 308 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 296 media titles]
2026-08-06 15:10
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 296 media titles]
2026-08-04 07:00
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 292 media titles]
2026-08-04 14:30
Most Read
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
2026-08-04 07:00
11665
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
9425
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
2026-08-04 06:00
8157
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
2026-08-04 14:30
7810